1. You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F#, Kim BYS#, Lee AS#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 2023;1-13. # = co-corresponding author. Impact Factor = 29.23
2. Li X, Lu WJ, Li Y, Wu F, Bai R, Na S, Dong T, Zhang H, Lee AS#, Wang Y#, Lan F#. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling. Cell Death and Disease 2019;8(13):1-15. # = co-corresponding author. Impact Factor = 12.07
3. Lee AS*, Inayathullah M*, Lijkwan M*, Zhao X, Sun W, Park S, Hong WX, Parekh M, Malkovskiy, Lau E, Qin X, Pothineni V, Sanchez-Freire V, Zhang W, Kooreman N, Ebert A, Chan C, Nguyen PK, Rajadas J, Wu JC. A novel slow release collagen matrix cross-linked with pro-survival factor analogs promotes stem cell survival for treatment of ischemic cardiovascular disease. Nature Biomedical Engineering 2018;2(2):104-113. Impact Factor = 29.23 *=equal contribution
4. Chan CK, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, Tevlin R, Wearda T, Lu W, Senarath-Yapa K, Chung MT, Marecic O, Tran M, Yan KS, Upton R, Walmsley GG, Lee AS, Sahoo D, Kuo CJ, Weissman IL, Longaker MT. Identification and specification of the mouse skeletal stem cell. Cell 2015;160(1-2):285-298. Impact Factor = 41.58
5. Mordwinkin NM, Lee AS, Wu JC. Patient-specific stem cells and cardiovascular drug discovery. Journal of the American Medical Association 2013;310(19):2039-2040. Impact Factor = 157.3
6. Lee AS*, Tang C*, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nature Medicine 2013; 19(8):998-1004. *=equal contribution. Impact Factor = 87.24
7. Liang P*, Lan F*, Lee AS*, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Nguyen PK, Wang PJ, Bers DM Robbins RC, Wu JC. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013;127(16):1677-91. *=equal contribution. [Best Basic Science Manuscript Circulation 2014]. Impact Factor = 39.92
8. Lan F*, Lee AS*, Liang P*, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12 (1): 101-13. *=equal contribution. Impact Factor = 24.63
9. Tang C, Lee AS, Volkmer J, Sahoo D, Nag D, Mosley A, Inlay MA, Ardehali R, Chavez SL, Reijo Pera R, Behr B, Wu JC, Weissman IL, Drukker M. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nature Biotechnology 2011;29(9): 829-34. [*Journal Cover]. Impact Factor = 68.16
10. Pearl JI, Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011;8(3):309-317. Impact Factor = 24.63
11. Sun N*, Lee A*, Wu JC. Long Term Non-Invasive Imaging of Embryonic Stem Cells Using Reporter Genes. Nature Protocols 2009;4(8):1192-201 *=equal contribution. Impact Factor = 13.49
1. You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F#, Kim BYS#, Lee AS#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 2023;1-13. # = co-corresponding author. Impact Factor = 29.23
2. Li X, Lu WJ, Li Y, Wu F, Bai R, Na S, Dong T, Zhang H, Lee AS#, Wang Y#, Lan F#. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling. Cell Death and Disease 2019;8(13):1-15. # = co-corresponding author. Impact Factor = 12.07
3. Lee AS*, Inayathullah M*, Lijkwan M*, Zhao X, Sun W, Park S, Hong WX, Parekh M, Malkovskiy, Lau E, Qin X, Pothineni V, Sanchez-Freire V, Zhang W, Kooreman N, Ebert A, Chan C, Nguyen PK, Rajadas J, Wu JC. A novel slow release collagen matrix cross-linked with pro-survival factor analogs promotes stem cell survival for treatment of ischemic cardiovascular disease. Nature Biomedical Engineering 2018;2(2):104-113. Impact Factor = 29.23 *=equal contribution
4. Chan CK, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, Tevlin R, Wearda T, Lu W, Senarath-Yapa K, Chung MT, Marecic O, Tran M, Yan KS, Upton R, Walmsley GG, Lee AS, Sahoo D, Kuo CJ, Weissman IL, Longaker MT. Identification and specification of the mouse skeletal stem cell. Cell 2015;160(1-2):285-298. Impact Factor = 41.58
5. Mordwinkin NM, Lee AS, Wu JC. Patient-specific stem cells and cardiovascular drug discovery. Journal of the American Medical Association 2013;310(19):2039-2040. Impact Factor = 157.3
18. Lee AS*, Tang C*, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nature Medicine 2013; 19(8):998-1004. *=equal contribution. Impact Factor = 87.24
6. Liang P*, Lan F*, Lee AS*, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Nguyen PK, Wang PJ, Bers DM Robbins RC, Wu JC. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013;127(16):1677-91. *=equal contribution. [Best Basic Science Manuscript Circulation 2014]. Impact Factor = 39.92
7. Lan F*, Lee AS*, Liang P*, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12 (1): 101-13. *=equal contribution. Impact Factor = 24.63
8. Tang C, Lee AS, Volkmer J, Sahoo D, Nag D, Mosley A, Inlay MA, Ardehali R, Chavez SL, Reijo Pera R, Behr B, Wu JC, Weissman IL, Drukker M. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nature Biotechnology 2011;29(9): 829-34. [*Journal Cover]. Impact Factor = 68.16
9. Pearl JI, Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011;8(3):309-317. Impact Factor = 24.63
10. Sun N*, Lee A*, Wu JC. Long Term Non-Invasive Imaging of Embryonic Stem Cells Using Reporter Genes. Nature Protocols 2009;4(8):1192-201 *=equal contribution. Impact Factor = 13.49